Resolving Inflammation Through Melanocortin Biology
Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation. SynAct’s therapeutics are designed to selectively provide anti-inflammatory and pro-resolution effects without suppressing the immune system, an emerging approach known as Inflammation Resolution.
AP1189
A Novel and First-in-Class Agent to Target the Melanocortin System
Our lead drug candidate AP1189, a once-daily oral selective melanocortin agonist, specifically stimulates melanocortin receptors – a distinct mode of action compared to approved anti-inflammatory drugs which can be immunosuppressive. SynAct is currently evaluating AP1189 in rheumatoid arthritis (RA), in idiopathic membranous nephropathy (iMN, an autoimmune disease associated with the development of nephrotic syndrome) and in the treatment of respiratory insufficiency caused by COVID-19 infection.
A Pipeline Targeted on Unmet Therapeutic Needs
Robust clinical development programs in Rheumatoid Arthritis, idiopathic membranous nephropathy (iMN), and in COVID-19 infection to prevent respiratory insufficiency, the most common cause of death among COVID-19 patients.
-
November 23, 2021 Non RegulatorySynAct Pharma reports positive PK data on AP1189 tablets
-
November 19, 2021 Non RegulatorySynAct Pharma announces Nomination Committee in respect of AGM 2022
-
November 12, 2021 RegulatoryInterim report Q3 2021
-
August 27, 2021 RegulatorySynAct Pharma: Interim Report January-June 2021 August 27, 2021 (Q2 2021 Report included)
A Management Team Committed to Success
An experienced team driven to help address areas of unmet therapeutic need while building value for shareholders. SynAct Pharma leads the emerging field of Resolution Therapy.